Combining Ivermectin, Mebendazole & Fenbendazole to Treat Cancer - Quick Reference Sheet
evipedia.ai
← Back

Combining Ivermectin, Mebendazole & Fenbendazole to Treat Cancer

Created on 09/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Three inexpensive antiparasitic medications combined to attack tumour cells from different directions. The laboratory case is consistent; the human case is thin and uneven. Only mebendazole has controlled trial data, and it conflicts. Fenbendazole has never been studied in people. Recorded harms — liver injury, suppressed blood-cell production, severe skin reactions, interference with cancer care — are more certain than benefits. (Full Review)

Protocol

Standard combined regimen
Ivermectin 25 mg + mebendazole 250 mg, once daily
One compounded capsule, 6 days per week — a 1:10 ratio, administered with the largest fat-containing meal.
Fenbendazole substitution
Fenbendazole 222 mg daily, 3 days on, 4 days off
Where fenbendazole replaces mebendazole, repeated weekly, with ivermectin on dosing days only.
Weight-based escalation
Ivermectin toward 1 mg/kg, mebendazole 500–1,000 mg daily
For aggressive disease, retaining simultaneous once-daily administration.
Time to effect
Parasite clearance
Single dose
Single-dose mebendazole cured most roundworm infections.
Tumour response assessment
8–12 weeks
Imaging or tumour-marker change is not assessed earlier in any published protocol.
Outcome horizon
6 months
The observational cohort measured outcomes at six months; shorter horizons cannot separate effect from natural variation.

Benefits

Contraindications
  • Metronidazole: concurrent use with mebendazole
  • Pregnancy, particularly the first trimester, and breastfeeding
  • Child-Pugh Class B or C hepatic impairment, or baseline ALT above 3 times the upper limit of normal
  • Absolute neutrophil count below 1.5 × 10⁹/L or platelets below 100 × 10⁹/L
  • Known Loa loa exposure or microfilarial load above 8,000 microfilariae/mL
  • Known ABCB1 loss-of-function genotype or prior ivermectin-associated neurological event
  • Body weight below 15 kg or age under 5 years
    •
Key Interactions
  • Strong CYP3A4 inhibitors (ketoconazole, grapefruit juice): caution
  • CYP3A4 inducers (rifampicin, St John's wort): caution
  • Ritonavir and other protease inhibitors: caution
  • Warfarin and direct oral anticoagulants (apixaban): monitor
  • Other hepatotoxic drugs (methotrexate, checkpoint inhibitors): caution
  • Myelosuppressive chemotherapy (platinum): monitor
  • Microtubule-targeting agents (paclitaxel): caution
  • Cimetidine: monitor
  • Over-the-counter sedating antihistamines (diphenhydramine) and alcohol: caution
  • P-glycoprotein-inhibiting supplements (quercetin, curcumin, cannabidiol): caution
  • Additive hepatotoxic supplements (green tea extract, kava): caution
  • Additive microtubule-active supplements (colchicine, noscapine): caution

Risk & Side Effects

  • High: Gastrointestinal adverse events; hepatotoxicity and drug-induced liver injury
  • Medium: Bone-marrow suppression at high mebendazole doses; hypersensitivity and severe skin reactions
  • Low: Ivermectin neurotoxicity; reproductive toxicity in pregnancy; rapid disease progression on high-dose mebendazole; displacement of or interference with established cancer treatment; glomerulonephritis and alopecia on prolonged high-dose mebendazole
  • Speculative: Mutual pharmacokinetic interference between the three agents

Monitoring

Marker Target Why
ALT 10–26 U/L (men), 8–22 U/L (women) Earliest signal of hepatocellular injury
AST 10–26 U/L Grades hepatocellular injury alongside ALT
GGT Below 20 U/L (men), below 15 U/L (women) Most sensitive marker of cholestatic injury
Total bilirubin 0.3–1.0 mg/dL Defines clinically significant injury alongside a raised ALT
Alkaline phosphatase 50–90 U/L Separates cholestatic from hepatocellular injury patterns
Absolute neutrophil count 2.0–5.0 × 10⁹/L Detects marrow suppression limiting high-dose mebendazole
Haemoglobin 14–15 g/dL (men), 13.5–14.5 g/dL (women) Tracks the anaemia seen on high-dose mebendazole
Platelets 200–350 × 10⁹/L Completes the marrow picture
Albumin 4.2–5.0 g/dL Governs the free fraction of these protein-bound drugs
eGFR Above 90 mL/min/1.73 m² Confirms renal reserve for clearing metabolites
hs-CRP Below 0.5 mg/L Tracks systemic inflammatory burden
Disease-specific tumour marker Direction and slope against the pre-treatment baseline The only biochemical read-out of disease trajectory

Cadence: Liver panel and complete blood count at 1, 2 and 4 weeks, then every 4–8 weeks; renal function, albumin and inflammatory markers every 3 months; tumour markers and imaging every 8–12 weeks. Any dose escalation resets the 2-week interval.

Qualitative Assessment

  • Energy levels and exercise tolerance, which fall early with developing anaemia
  • Appetite and nausea severity, the most common reason regimens are abandoned
  • Right upper abdominal discomfort, itch or dark urine, each an early symptom of liver injury
  • Cognitive clarity, balance and any visual disturbance, which would signal ivermectin central nervous system penetration
  • Pain scores and analgesic requirement, often the earliest patient-perceptible change in disease activity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.